Abstract
The focus of aging research has shifted from increasing lifespan to enhancing healthspan to reduce the time spent living with disability. Despite significant efforts to develop biomarkers of aging, few studies have focused on biomarkers of healthspan. We developed a proteomics-based signature of healthspan (healthspan proteomic score (HPS)) using proteomic data from the Olink Explorer 3072 assay in the UK Biobank Pharma Proteomics Project (53,018 individuals and 2920 proteins). A lower HPS was associated with higher mortality risk and several age-related conditions, such as COPD, diabetes, heart failure, cancer, myocardial infarction, dementia, and stroke. HPS showed superior predictive accuracy for these outcomes compared to other biological age measures. Proteins associated with HPS were enriched in hallmark pathways such as immune response, inflammation, cellular signaling, and metabolic regulation. The external validity was established using the Essential Hypertension Epigenetics study with proteomic data also from the Olink Explorer 3072 and complementary epigenetic data, making it a valuable tool for assessing healthspan and as a potential surrogate marker to complement existing proteomic and epigenetic biological age measures in geroscience-guided studies.
Significance Despite substantial efforts to develop biomarkers of aging, few studies have focused on biomarkers of healthspan. The challenge lies in the need for long follow-up periods and large sample sizes of healthy individuals to observe aging outcomes. Therefore, developing surrogate biomarkers that can predict healthspan is crucial. We addressed this by developing a proteomics-based signature of healthspan, termed the Healthspan Proteomic Score (HPS), in a healthy cohort. We demonstrated its clinical, predictive, and biological validity in the UK Biobank and Essential Hypertension Epigenetics study, which represents a focused subset of the Finland Twin Cohort. The HPS, serving as a surrogate marker of healthspan, is useful for gauging an individual’s biological health and monitoring the impact of geroscience-guided interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Access to UK Biobank data was granted under application no. 92647 Research to Inform the Field of Precision Gerontology (PI: Richard H. Fortinsky), funded by the Claude D. Pepper Older American Independence Centers (OAIC) program: P30AG067988 (MPIs: George A. Kuchel and Richard H. Fortinsky). CLK, BSD, RHF, and GAK are partially supported by P30AG067988. JLA has a UK National Institute for Health and Care Research (NIHR) Advanced Fellowship (NIHR301844). MO, EV, and JK acknowledge support from the Sigrid Juselius Foundation. GD has been supported by the doctoral programs of the University of Helsinki. Data collection in the twin cohort has been supported by the Academy of Finland (grants 100499, 205585, 118555, 141054, 264146, 308248 to JK, and 307339 and 328685 to MO) and Academy of Finland Center of Excellence in Complex Disease Genetics (grant 352792 to JK).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to UK Biobank data was granted under application no. 92647 Research to Inform the Field of Precision Gerontology (PI: Richard H. Fortinsky). This research used data assets made available by National Safe Haven as part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (research which commenced between 1 October 2020-31 March 2021 grant ref MC_PC_20029; 1 April 2021-30 September 2022 grant ref MC_PC_20058). This research also used data provided by patients and collected by the NHS as part of their care and support. Copyright (year), NHS England. Re-used with the permission of the NHS England [and/or UK Biobank]. All rights reserved.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Co-first authors
The manuscript has been revised to address the reviewer's critiques (PNAS), particularly including replication results from an external cohort.
Data Availability Statements
Data access to the UK Biobank is granted upon application. The EH-Epi study data used in the analysis is available through the Biobank of the Finnish Institute for Health and Welfare (https://thl.fi/en/web/thl-biobank/forresearchers). It is available to researchers after written application and following the relevant Finnish legislation. The R code (Liu & Kuo n.d.) for computing HPS can be obtained from the GitHub repository at https://github.com/kuo-lab-uchc/HPS.
